GSEP
ABBV icon

Golden State Equity Partners’s AbbVie ABBV Stock Holding History

Golden State Equity Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196K Sell
778
-36,015
-98% -$7.75M 0.53% 27
2026
Q1 		$8M Buy
36,793
+16,953
+85% +$3.76M 0.61% 26
2025
Q4 		$4.53M Buy
19,840
+2,735
+16% +$623K 0.73% 20
2025
Q3 		$3.96M Sell
17,105
-3,143
-16% -$640K 0.67% 27
2025
Q2 		$3.76M Buy
20,248
+57
+0.3% +$10.6K 0.7% 25
2025
Q1 		$4.23M Sell
20,191
-363
-2% -$70.6K 0.84% 18
2024
Q4 		$3.65M Sell
20,554
-1,764
-8% -$324K 0.7% 26
2024
Q3 		$4.41M Buy
22,318
+5,740
+35% +$1.07M 0.69% 25
2024
Q2 		$2.84M Buy
+16,578
New +$2.75M 0.59% 33
2023
Q4 		$2.57M Sell
16,573
-254
-2% -$37K 0.62% 36
2023
Q3 		$2.51M Sell
16,827
-182
-1% -$26.7K 0.7% 34
2023
Q2 		$2.29M Buy
17,009
+5,617
+49% +$824K 0.64% 32
2023
Q1 		$1.82M Buy
+11,392
New +$1.74M 0.98% 29
2022
Q1 		$1.11M Buy
6,864
+1,024
+18% +$149K 0.56% 54
2021
Q4 		$791K Sell
5,840
-3,809
-39% -$450K 0.4% 62
2021
Q3 		$1.04M Buy
9,649
+4,549
+89% +$520K 0.42% 58
2021
Q2 		$574K Buy
+5,100
New +$574K 0.22% 112

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Golden State Equity Partners's ABBV Position: Q2 2026 in Review

Golden State Equity Partners reduced its AbbVie (ABBV) stake by 98% in Q2 2026, selling an estimated $7.75M and leaving 778 shares worth $196K. The position accounts for 0.53% of the portfolio, ranked #27.

Golden State Equity Partners first reported a position in ABBV in Q2 2021 and has held it in 17 quarters since. The position peaked at $8M in Q1 2026. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Golden State Equity Partners held 778 shares of AbbVie worth $196K as of Q2 2026.
  • Golden State Equity Partners sold 36,015 AbbVie shares in Q2 2026, an estimated $7.75M.
  • AbbVie made up 0.53% of Golden State Equity Partners's portfolio in Q2 2026, its #27 holding.
  • Golden State Equity Partners first reported a position in AbbVie in Q2 2021 and has held it in 17 quarters since.
  • Golden State Equity Partners's AbbVie position peaked at $8M in Q1 2026.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.